Back to results
US 12,747,432 B2Granted
Modulating human Cas9-specific host immune response
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsRadwa Ewaisha, Samira Kiani, Shayesteh Roshdi Ferdosi, Karen Anderson, Farzaneh Moghadam, Sri Krishna, Mo Reza Ebrahimkhani
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for reducing an undesirable T cell immune response in human patients prior to and/or during gene therapy using CRISPR/Cas9-based genetic modulation.
Claims3
An isolated polynucleotide encoding a variant Cas9 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, SEQ ID NO:
- 3, or SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.